Activation of TLR4 induces VEGF expression via Akt pathway in nasal polyps

Clinical and Experimental Allergy

Volumn 43, Issue 9, 2013, Pages 1038-1047

  Cho, J S ^a,b   Kang, J H ^a   Han, I H ^a   Um, J Y ^a   Lee, H M ^a,b  

^a Korea University College of Medicine   (South Korea)

^b Korea University College of Medicine   (South Korea)

Author keywords

Fibroblasts; LPS; Nasal polyposis; TLR; VEGF

Indexed keywords

LIPOPOLYSACCHARIDE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN KINASE B; TOLL LIKE RECEPTOR 4; VASCULOTROPIN;

ARTICLE; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; FIBROBLAST; GENE ACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; MACROPHAGE; NOSE POLYP; ODONTOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHODOBACTER SPHAEROIDES; SIGNAL TRANSDUCTION; TURBINATE; WESTERN BLOTTING;

FIBROBLASTS; LPS; NASAL POLYPOSIS; TLR; VEGF;

ENZYME ACTIVATION; FIBROBLASTS; GENE EXPRESSION REGULATION; HUMANS; LIPOPOLYSACCHARIDES; MAP KINASE SIGNALING SYSTEM; NASAL POLYPS; ORGAN CULTURE TECHNIQUES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4; TRANSCRIPTOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84882784912     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/cea.12165     Document Type: Article

References (33)

1. Pawankar R. Nasal polyposis: an update: editorial review. Curr Opin Allergy Clin Immunol 2003; 3:1-6.
2. Shin SH, Ponikau JU, Sherris DA et al. Chronic rhinosinusitis: an enhanced immune response to ubiquitous airborne fungi. J Allergy Clin Immun 2004; 114:1369-75.
3. Tammela T, Enholm B, Alitalo K, Paavonen K. The biology of vascular endothelial growth factors. Cardiovasc Res 2005; 65:550-63.
4. Ferrara N, Houck K, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 1992; 13:18-32.
5. Coste A, Brugel L, Maitre B et al. Inflammatory cells as well as epithelial cells in nasal polyps express vascular endothelial growth factor. Eur Respir J 2000; 15:367-72.
6. Lee HS, Myers A, Kim J. Vascular endothelial growth factor drives autocrine epithelial cell proliferation and survival in chronic rhinosinusitis with nasal polyposis. Am J Respir Crit Care Med 2009; 180:1056-67.
7. Gosepath J, Brieger J, Lehr HA, Mann WJ. Expression, localization, and significance of vascular permeability/vascular endothelial growth factor in nasal polyps. Am J Rhinol 2005; 19:7-13.
8. Drexler SK, Foxwell BM. The role of Toll-like receptors in chronic inflammation. Int J Biochem Cell B 2010; 42:506-18.
9. Vandermeer J, Sha Q, Lane AP, Schleimer RP. Innate immunity of the sinonasal cavity: expression of messenger RNA for complement cascade components and toll-like receptors. Arch Otolaryngol Head Neck Surg 2004; 130:1374-80. Erratum in Arch Otolaryngol Head Neck Surg 2005, 131:406.
10. Hoshino K, Takeuchi O, Kawai T et al. Cutting edge: toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol 1999; 162:3749-52.
11. Ramanathan M, Giladi A, Leibovich SJ. Regulation of vascular endothelial growth factor gene expression in murine macrophages by nitric oxide and hypoxia. Exp Biol Med (Maywood) 2003; 228:697-705.
12. Botero TM, Shelburne CE, Holland GR, Hanks CT, Nor JE. TLR4 mediates LPS-induced VEGF expression in odontoblasts. J Endod 2006; 32:951-5.
13. Visintin A, Halmen KA, Latz E, Monks BG, Golenbock DT. Pharmacological inhibition of endotoxin responses is achieved by targeting the TLR4 coreceptor, MD-2. J Immunol 2005; 175:6465-72.
14. Saitoh S, Akashi S, Yamada T et al. Lipid A antagonist, lipid IVa, is distinct from lipid A in interaction with Toll-like receptor 4 (TLR4)-MD-2 and ligand-induced TLR4 oligomerization. Int Immunol 2004; 16:961-9.
15. Cho JS, Moon YM, Park IH et al. Epigenetic regulation of myofibroblast differentiation and extracellular matrix production in nasal polyp-derived fibroblasts. Clin Exp Allergy 2012; 42:872-82.
16. Park SK, Jang WH, Yang YI. Expression of pro-angiogenic cytokines and their inhibition by dexamethasone in an ex vivo model of nasal polyps. Biochem Biophys Res Commun 2009; 379:255-60.
17. Wang JH, Kwon HJ, Chung YS, Lee BJ, Jang YJ. Infection rate and virus-induced cytokine secretion in experimental rhinovirus infection in mucosal organ culture: comparison between specimens from patients with chronic rhinosinusitis with nasal polyps and those from normal subjects. Arch Otolaryngol Head Neck Surg 2008; 134:424-7.
18. Shin SH, Lee YH. Airborne fungi induce nasal polyp epithelial cell activation and Toll-like receptor expression. Int Arch Allergy Immunol 2010; 153:46-52.
19. Senger DR, Van de Water L, Brown LF et al. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev 1993; 12:303-24.
20. Wittekindt C, Hess A, Bloch W, Sultanie S, Michel O. Immunohistochemical expression of VEGF and VEGF receptors in nasal polyps as compared to normal turbinate mucosa. Eur Arch Otorhinolaryngol 2002; 259:294-8.
21. Hu KH, Lee FP, Cheng YJ, Huang HM. Vascular endothelial growth factor and children featuring nasal polyps. Int J Pediatr Otorhinolaryngol 2007; 71:23-8.
22. Payne SC, Early SB, Huyett P, Han JK, Borish L, Steinke JW. Evidence for distinct histologic profile of nasal polyps with and without eosinophilia. Laryngoscope 2011; 121:2262-7.
23. Early SB, Hise K, Han JK, Borish L, Steinke JW. Hypoxia stimulates inflammatory and fibrotic responses from nasal-polyp derived fibroblasts. Laryngoscope 2007; 117:511-5.
24. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth-factor is a secreted angiogenic mitogen. Science 1989; 246:1306-9.
25. Paavonen K, Horelli-Kuitunen N, Chilov D et al. Novel human vascular endothelial growth factor genes VEGF-B and VEGF-C localize to chromosomes 11q13 and 4q34, respectively. Circulation 1996; 93:1079-82.
26. Joukov V, Pajusola K, Kaipainen A et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 1996; 15:290-8.
27. Karkkainen MJ, Haiko P, Sainio K et al. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol 2004; 5:74-80.
28. Ristimaki A, Narko K, Enholm B, Joukov V, Alitalo K. Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C. J Biol Chem 1998; 273:8413-8.
29. Islam MA, Cinar MU, Uddin MJ et al. Expression of Toll-like receptors and downstream genes in lipopolysaccharide-induced porcine alveolar macrophages. Vet Immunol Immunopathol 2012; 146:62-73.
30. Christianson CA, Dumlao DS, Stokes JA et al. Spinal TLR4 mediates the transition to a persistent mechanical hypersensitivity after the resolution of inflammation in serum-transferred arthritis. Pain 2011; 152:2881-91.
31. Botero TM, Son JS, Vodopyanov D, Hasegawa M, Shelburne CE, Nor JE. MAPK signaling is required for LPS-induced VEGF in pulp stem cells. J Dent Res 2010; 89:264-9.
32. Cho EJ, An HJ, Shin JS et al. Roxatidine suppresses inflammatory responses via inhibition of NF-kappaB and p38 MAPK activation in LPS-induced RAW 264.7 macrophages. J Cell Biochem 2011; 112:3648-59.
33. Ren XS, Sato Y, Harada K et al. Biliary infection may exacerbate biliary cystogenesis through the induction of VEGF in cholangiocytes of the polycystic kidney (PCK) rat. Am J Pathol 2011; 179:2845-54.